Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Net Income (2016 - 2025)

Historic Net Income for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $52.8 million.

  • Catalyst Pharmaceuticals' Net Income rose 2027.85% to $52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $217.1 million, marking a year-over-year increase of 6579.36%. This contributed to the annual value of $163.4 million for FY2024, which is 17443.4% up from last year.
  • Catalyst Pharmaceuticals' Net Income amounted to $52.8 million in Q3 2025, which was up 2027.85% from $52.1 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Net Income ranged from a high of $56.7 million in Q1 2025 and a low of -$30.8 million during Q3 2023
  • Moreover, its 5-year median value for Net Income was $23.3 million (2024), whereas its average is $26.7 million.
  • In the last 5 years, Catalyst Pharmaceuticals' Net Income plummeted by 23523.83% in 2023 and then skyrocketed by 24264.73% in 2024.
  • Catalyst Pharmaceuticals' Net Income (Quarter) stood at $9.3 million in 2021, then soared by 173.62% to $25.5 million in 2022, then decreased by 9.82% to $23.0 million in 2023, then skyrocketed by 141.33% to $55.4 million in 2024, then decreased by 4.78% to $52.8 million in 2025.
  • Its Net Income was $52.8 million in Q3 2025, compared to $52.1 million in Q2 2025 and $56.7 million in Q1 2025.